CL2022000904A1 - Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). - Google Patents

Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).

Info

Publication number
CL2022000904A1
CL2022000904A1 CL2022000904A CL2022000904A CL2022000904A1 CL 2022000904 A1 CL2022000904 A1 CL 2022000904A1 CL 2022000904 A CL2022000904 A CL 2022000904A CL 2022000904 A CL2022000904 A CL 2022000904A CL 2022000904 A1 CL2022000904 A1 CL 2022000904A1
Authority
CL
Chile
Prior art keywords
formula
preparation
vii
polymorph
div
Prior art date
Application number
CL2022000904A
Other languages
English (en)
Inventor
Song Xue
Vishnu Vardhan Reddy Karnati
Wayne C Schairer
Ahmad Hashash
Takashi Nakai
Debra Jane Wallace
Fenger Zhou
Yuguang Wang
William Kissel
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/en
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2022000904A1 publication Critical patent/CL2022000904A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procesos nuevos para la preparación de compuestos de Fórmula IV, VII y IA. Algunos de estos compuestos son de utilidad como estimulantes de la guanilato ciclasa soluble (sGC). Otros son intermediarios para usar en la preparación de dichos estimulantes. Estos procesos son adecuados para preparaciones a gran escala y producen 3-(2-pirimidinil)pirazoles de la Fórmula I estables, de gran pureza y rendimientos elevados. La invención ofrece la ventaja adicional de comprender condiciones de reacción sencillas, adecuadas para aumentar la escala en una producción a gran escala. También se proveen nuevos intermediarios para usar en la preparación de dichos compuestos.
CL2022000904A 2018-01-10 2022-04-08 Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814). CL2022000904A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (en) 2018-02-22 2018-02-22 Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
CL2022000904A1 true CL2022000904A1 (es) 2022-10-21

Family

ID=65279655

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020001814A CL2020001814A1 (es) 2018-01-10 2020-07-07 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
CL2022000904A CL2022000904A1 (es) 2018-01-10 2022-04-08 Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
CL2022000907A CL2022000907A1 (es) 2018-01-10 2022-04-08 Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020001814A CL2020001814A1 (es) 2018-01-10 2020-07-07 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000907A CL2022000907A1 (es) 2018-01-10 2022-04-08 Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814).

Country Status (17)

Country Link
US (3) US11274096B2 (es)
EP (2) EP4249469A3 (es)
JP (2) JP7357621B2 (es)
KR (1) KR20200106920A (es)
CN (1) CN111902410B (es)
AU (2) AU2019206560B2 (es)
BR (1) BR112020013985A2 (es)
CA (1) CA3087943A1 (es)
CL (3) CL2020001814A1 (es)
ES (1) ES2963447T3 (es)
IL (1) IL275748A (es)
JO (1) JOP20200165A1 (es)
MA (1) MA51565A (es)
MX (3) MX2020007364A (es)
SG (1) SG11202006311SA (es)
TW (2) TWI821237B (es)
WO (1) WO2019140095A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000291A2 (pt) * 2016-07-07 2019-04-16 Ironwood Pharmaceuticals Inc processos inovadores para a preparação de estimuladores de guanilato ciclase solúvel
ES2963447T3 (es) 2018-01-10 2024-03-27 Cyclerion Therapeutics Inc Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5860459B2 (ja) * 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激薬
BR112015023349A2 (pt) 2013-03-15 2017-07-18 Ironwood Pharmaceuticals Inc composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
US20160324856A1 (en) * 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
AU2015317824A1 (en) * 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
US10047095B2 (en) * 2014-09-17 2018-08-14 Ironwood Pharmaceuticals, Inc. sGC stimulators
EP3383372B1 (en) * 2015-11-30 2023-11-01 Cyclerion Therapeutics, Inc. Solid dispersions comprising a sgc stimulator
CN109563086B (zh) 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
BR112019000291A2 (pt) 2016-07-07 2019-04-16 Ironwood Pharmaceuticals Inc processos inovadores para a preparação de estimuladores de guanilato ciclase solúvel
ES2963447T3 (es) 2018-01-10 2024-03-27 Cyclerion Therapeutics Inc Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble

Also Published As

Publication number Publication date
KR20200106920A (ko) 2020-09-15
US20230339928A1 (en) 2023-10-26
US20210053962A1 (en) 2021-02-25
MX2023000044A (es) 2023-02-01
MX2023000045A (es) 2023-02-01
CL2020001814A1 (es) 2020-11-06
TW201932450A (zh) 2019-08-16
EP4249469A3 (en) 2023-12-27
CA3087943A1 (en) 2019-07-18
CN111902410A (zh) 2020-11-06
US11708361B2 (en) 2023-07-25
JP7357621B2 (ja) 2023-10-06
EP3737679B1 (en) 2023-09-06
US11274096B2 (en) 2022-03-15
MA51565A (fr) 2020-11-18
BR112020013985A2 (pt) 2020-12-01
CL2022000907A1 (es) 2022-10-21
WO2019140095A8 (en) 2020-06-18
CN111902410B (zh) 2024-04-19
EP4249469A2 (en) 2023-09-27
TW202402741A (zh) 2024-01-16
MX2020007364A (es) 2020-11-18
US20220024909A1 (en) 2022-01-27
TWI821237B (zh) 2023-11-11
JOP20200165A1 (ar) 2022-10-30
ES2963447T3 (es) 2024-03-27
AU2019206560B2 (en) 2023-08-24
AU2023270260A1 (en) 2023-12-07
JP2023182647A (ja) 2023-12-26
EP3737679C0 (en) 2023-09-06
SG11202006311SA (en) 2020-07-29
JP2021511299A (ja) 2021-05-06
WO2019140095A1 (en) 2019-07-18
IL275748A (en) 2020-08-31
AU2019206560A1 (en) 2020-07-30
EP3737679A1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
CL2022000904A1 (es) Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
EA202090917A1 (ru) Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
AR048875A1 (es) Un proceso para preparar montelukast y compuestos intermedios para el mismo
MX2022001495A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
MX2018014128A (es) 6.7.beta-epoxidos esteroideos como intermedios quimicos.
AR118647A1 (es) Proceso de preparación de 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-deoxi-1-metilamino-d-glucitol
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
CL2020003015A1 (es) Conversión a escala preparativa de goniautoxinas en neosaxitoxina
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
WO2020127208A8 (en) Pharmaceutical process and intermediates
CU20220013A7 (es) Proceso industrial para la preparación de estetrol de alta pureza
AR098053A1 (es) Proceso para la síntesis industrial de lurasidona
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
CU20200047A7 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
CO2022001513A2 (es) Proceso e intermediarios para la preparación de piroxasulfona
CO2021015370A2 (es) Proceso de preparación de compuestos de estrobilurina activos como fungicidas e intermedios de los mismos
MX2023000059A (es) Metodo de preparacion de compuesto de fenilisoxazolina.
EA202091664A1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
JP2016108332A (ja) アミノ化合物の製造方法
PE20230183A1 (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina
WO2018207191A8 (en) Preparation of 2-cyclohexyliden-2-phenyl acetonitrile and odoriferous structural analogs thereof
UA123716U (uk) Обетіхолева кислота